Presentations

      Alterations of the Sputum Proteome and Transcriptome and Serum Lipidome from Smokers and Early-Stage COPD Subjects

      Schneider, T.
      Conference date
      Jul 6, 2017
      Conference name
      5th International Conference on Analytical Proteomics (ICAP) 2017
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Application of Systems Pharmacology to Identify Exposure Response Markers in Peripheral Blood After Switching to a Candidate Modified Risk Tobacco Product: the Tobacco Heating System 2.1 (THS 2.1)

      Clinical Systems Toxicology

      Human Research Investigation on the Effects of Cigarette Smoking, E-Cigarette Vaping, and Smoking Cessation on Vascular Cell Biology

      Clinical Systems Toxicology

      Alterations in the sputum proteome and transcriptome in smokers and early-stage COPD subjects

      Clinical Systems Toxicology

      Mechanistic evaluation of the impact of smoking and chronic obstructive pulmonary disease on the nasal epithelium

      Clinical Systems Toxicology

      Alterations in serum polyunsaturated fatty acids and eicosanoids in patients with mild to moderate chronic obstructive pulmonary disease (COPD)

      Clinical Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.